Dean Destructo
New member
<abstracttext label="RESULTS" nlmcategory="RESULTS">Testosterone substitution resulted in significant decrements of serum levels of low-density lipoprotein-cholesterol, resting diastolic and systolic blood pressure, and heart rate. Erythropoiesis was stimulated and concentrations of high-density lipoprotein cholesterol increased. Parameters remained stable after four injections. No adverse effects regarding the prostate were observed. Significantly increased hematocrit greater than 50% was predicted by enhanced androgen action (shorter AR CAG repeats per higher testosterone levels). However, insufficient androgen action (longer AR CAG repeats per lower testosterone levels) caused pathological safety parameters (high blood pressure, adverse lipid profiles). In addition, a body mass index 30 kg/m(2) or greater represents a clinically relevant factor for the occurrence of all pathological safety parameters. Risk calculations for obese patients and nonlinear pharmacokinetic models to tailor androgen substitution are presented.</abstracttext>
[h=4]CONCLUSIONS:[/h]<abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">Testosterone substitution with im TU is generally well tolerated. Modifications of androgen action are due to both AR CAG repeats and testosterone levels. Adverse observations are mostly seen in obese patients.
** total of 515 data time points each related to prostate, erythropoiesis, lipoproteins, and circulation during 118 treatment-years with 1000 mg TU at 10- to 14-wk intervals.
Patients included 66 hypogonadal men (mean age 38 +/- 9.9 yr).
source: </abstracttext>Zitzmann M1, Nieschlag E.
[h=4]CONCLUSIONS:[/h]<abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">Testosterone substitution with im TU is generally well tolerated. Modifications of androgen action are due to both AR CAG repeats and testosterone levels. Adverse observations are mostly seen in obese patients.
** total of 515 data time points each related to prostate, erythropoiesis, lipoproteins, and circulation during 118 treatment-years with 1000 mg TU at 10- to 14-wk intervals.
Patients included 66 hypogonadal men (mean age 38 +/- 9.9 yr).
source: </abstracttext>Zitzmann M1, Nieschlag E.
